Oral sildenafil in the treatment of erectile dysfunction

New England Journal of Medicine

Volumn 338, Issue 20, 1998, Pages 1397-1404

  Goldstein, Irwin ^a   Lue, Tom F ^b   Padma nathan, Harin ^c,d   Rosen, Raymond C ^e   Steers, William D ^f   Wicker, Pierre A ^g  

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d Male Clinic   (United States)

^e RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF VIRGINIA   (United States)

^g PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SILDENAFIL;

ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FLUSHING; HEADACHE; HUMAN; IMPOTENCE; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PENIS ERECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEXUAL INTERCOURSE; VISUAL IMPAIRMENT;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; COITUS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HUMANS; IMPOTENCE; MALE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; TREATMENT OUTCOME;

EID: 0032516296     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199805143382001     Document Type: Article

References (14)

1. NIH Consensus Development Panel on Impotence. Impotence. JAMA 1993;270:83-90.
2. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKjnlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61.
3. Age and sexual outlet. In: Kinsey AC, Pomeroy WB, Martin CE. Sexual behavior in the human male. Philadelphia: W.B. Saunders, 1948:218-62.
4. Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. N Engl J Med 1996;334:873-7.
5. Padma-Nathan H, Hellstrom WJG, Kaiser FE, et al. Treatment of men with erectile dysfunction with transurethral alprostadil. N Engl J Med 1997;336:1-7.
6. Montague DK, Barada JH, Belker AM, et al. Clinical Guidelines Panel on Erectile Dysfunction: summary report on the treatment of organic erectile dysfunction. J Urol 1996;156:2007-11.
7. Rajfer J, Aronson WJ, Bush PA, Dorey FJ, Ignarro LJ. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 1992;326:90-4.
8. Andersson K-E, Wagner G. Physiology of penile erection. Physiol Rev 1995;75:191-236.
9. Burnett AL. The role of nitric oxide in the physiology of erection. Biol Reprod 1995;52:485-9.
10. Boolell M, Allen MJ, Ballard SA, et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996;8:47-52.
11. Moreland RB, Goldstein I, Traish A. Sildenafil, a novel inhibitor of phosphodiesterase type 5 in human corpus cavernosum smooth muscle cells. Life Sci 1998;62:PL-309-PL-318.
12. Boolell M, Gepi-Attee S, Gingell JC, Allen MJ. Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br J Urol 1996;78:257-61.
13. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997;49:822-30.
14. Riley AJ, Athanasiadis L. Impotence and its non-surgical management. Br J Clin Pract 1997;51:99-103.